CYP2D6 Polymorphism in Patients of General Practice in Austria

Study Overview
=================
Brief Summary
-----------------
The CYP 2D6 enzyme metabolizes a significant number of drugs frequently prescribed in general practice/ family medicine. Various genetically different variants define if the patient is an ultra-rapid (UM), an normal (NM) (the normal case), an intermediate (IM) or a poor metabolizer (PM). It is estimated that approximately 20- 25 % of frequently described drugs are activated to more active or metabolized to ineffective or less effective drugs by CYP 2D6. Substrates of CYP 2D6 are mainly antidepressants, neuroleptics, opioids (e.g. codeine), beta-blockers, anti-arrhythmic drugs and various other single drugs. In case of an UM a drug can be metabolized too rapidly losing its therapeutic effect, requiring a higher dosage, or it can have a toxic effect, if it is converted too rapidly in the effective form (e.g. codeine). If metabolized too slowly (PM) it can accumulate and reach toxic levels. In this observational study (1) data relating to the number of patients of a single Austrian general practice receiving one or more drugs metabolized by CYP 2D6 are collected by extracting their electronic records of the last 3 years. In addition (2) consecutive patients with unknown genetic status of their CYP 2D6 enzyme visiting the surgery for a routine blood test due to various reasons, are additionally tested for their CYP 2D6 metabolizing status, if they actually take a drug metabolized by CYP 2D6. The aim of the study is to generate CYP 2D6 polymorphism data from Caucasian patients of an average Austrian general practice for the first time, which allows to group patients according to their NM, UM, IM and PM status. This can be of considerable clinical relevance when prescribing specific drugs. This study tries to investigate in how many patients the knowledge of the CYP 2D6 metabolizing status could have an influence on choosing the actually prescribed drug. In addition we plan to describe the distribution of frequent and relevant CYP 2D6 alleles including their combinations in patients of an average Austrian general practice for comparison reasons with other Caucasian populations.

Detailed Description
-----------------
Study population: Unselected consecutive patients of the practice office visiting the surgery for a routine blood sampling due to various medical conditions and who are prescribed or have been prescribed drugs metabolized by the CYP2D6 enzyme (or drugs being a strong inhibitor of CYP 2D6) during the last 3 years. Only in these patients CYP2D6 polymorphism is determined using a fraction of the EDTA-blood sample. No further genetic investigations or additional blood collections are performed. Patients who are considered to be eligible to participate in the study have to sign an informed consent after being informed about the aims of the study. Blood sampling and processing of the specimens: A standardized blood sampling using a Vacutainer system with filling of an EDTA tube (4 ml) for the red and white blood count is performed. 300 microliters of the collected blood are used for further determination of the CYP2D6 polymorphism. Isolation of DNA: DNA is extracted from EDTA blood in the practice laboratory by using the Spin Micro Extraction Kit® (ViennaLab,Vienna). The concentration and quality of DNA is measured using a Bio Photometer plus (Eppendorf). The extracted DNA is stored at -81°C in an ultra-low temperature deep freezer (U101-86, New Brunswick Scientific Co., Inc) without any further additives. Real-time PCR for determination of copy number of the CYP2D6 gene: For the determination of the copy number of the CYP2D6 gene a real-time PCR in triplicates on an ABI StepOnePlus by using the CYP2D6 RealFast™ CNV Assay (ViennaLab) is performed in the practice laboratory. The test is based on the fluorogenic 5' nuclease assay, also known as TaqMan® assay. Each reaction contains gene-specific primer pairs for amplification of CYP2D6 and endogenous control (EC) gene fragments with 141 bp each. Further components are two dual-labeled, gene-specific hydrolysis probes, the FAM-labeled CYP2D6 probe and the HEX-labeled EC probe, which hybridize to an internal sequence of the amplified fragments. The proximity of the 5'-fluorescent reporter and 3'-quencher dye on intact probes prevents the reporter from fluorescing. During the extension phase of PCR the 5' - 3' exonuclease activity of Taq DNA polymerase cleaves the 5'-fluorescent reporter from the hybridized probe. The physical separation of the fluorophore from the quencher dye generates a fluorescent signal in real-time, which is proportional to the accumulated PCR product. The CYP2D6 RealFast™ CNV Assay is a relative quantitation assay and compares the amount of both nucleic acid targets (CYP2D6 and EC) in relation to the CYP2D6 CNV Calibrator. The EC gene is used to normalize fluorescence signals between different samples and serves as a PCR positive control. For additional normalization of data ROX dye to a final concentration of 1 microliter to the 2 x Probe Mix is added. RT- PCR cycling conditions for the ABI StepOneplus cycler: Initial denaturation: 95°C 10 min 1 cycle; denaturation 95°C 15 sec 40 cycles; annealing /extension 60°C 1 min. PCR and hybridisation for CYP2D6 allele determination by the PGX-CYP2D StripAssay™: This assay is used for a subset of samples in this study and covers only 3 polymorphic loci: 1795delT (2D6*6), 1934G>A (2D6*4) and 2637delA (2D6*3). The test principle and procedure are similar to the PGX-CYP2D6 XL StripAssay® as described below but using different cycling conditions for the Palm-Cycler (Corbett Life Science): pre-PCR: 94°C/2 min; thermocycling: 94°C/15 sec.- 58°C/ 30 sec.-72°C/30 sec (35 cycles); final extension: 72°C/3 min. PCR and hybridisation for CYP2D6 allele determination by the PGX-CYP2D6 XL StripAssay®: For the determination of 19 clinically relevant CYP2D6 alleles (*1; *2 A, *2 B-M; *3, *4A-H, K, L or P, *4J or N, *4M; *5; *6 A, B or D, *6C; *7, *8; *9,; *10A or B, *10 C or D; *11; *12; *14; *15; *17; *29; *35; *39; *40 or *58; *41) a PCR amplification on a Palm-Cycler (Corbett Life Science, Eight Mile Plains, QLD 4113, Australia) using biotinylated primers is first performed. The amplification products are further hybridized to a test strip containing allele-specific oligonucleotide probes immobilized as an array of parallel lines. Bound biotinylated sequences are detected using streptavidin-alkaline phosphatase and color substrates. The evaluation of this reaction is done manually by using the StripAssay®-Evaluator (ViennaLab,Vienna), a proprietary PC program to determine the homozygous or heterozygous genotype. Cycling conditions for the Palm-Cycler (Corbett Life Science): pre-PCR: 95°C/4 min; thermocycling: 95°C/25 sec.- 60°C/ 45sec.-72°C/1min (36 cycles); final extension: 72°C/3 min. Statistics: The data were recorded and analyzed using Microsoft Excel Version 10 and the R Language and Environment for Statistical Computing and Graphics, Version 2.9. Standard methods are used for the description of data (frequencies and percentages for categorical data, mean and standard deviation for continuous data). To compare frequencies of CYP2D6-specific drugs prescribed in the single practice with the total number of the respective prescriptions in Lower Austria, Spearman's rank correlation-coefficient is calculated. Differences between groups were calculated by paired t-test. A p-value < 0.05 was considered to indicate statistical significance. The Hardy-Weinberg- equilibrium was calculated using Fisher´s Exact Chi-Square test due to the small numbers of genotypes.

Official Title
-----------------
CYP2D6 Polymorphism Defining UM, IM, NM and PM Status in Unselected Medically Treated Patients of General Practice in Austria

Conditions
-----------------
Disorder Due Cytochrome P450 CYP2D6 Variant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with clinical diagnosis of hypertension, diabetes, chronic heart failure, hyperlipidemias, depression, schizophrenia, cardial arrhythmias, thyroid diseases and dementia Exclusion Criteria: acute infectious diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of Metabolizer Status (PM, IM, NM, UM) in Patients | Remark: each participant possesses a) two individual CYP2D6 alleles, b) from the combination of these two alleles one individual genotype is derived and c) from this genotype the genetically determined metabolizer status (PM, IM, NM, UM) is derived. A patient can be considered a ultra-rapid (UM), a normal (NM), an intermediate (IM), or a poor metabolizer (PM) of a given drug | 1 Year | 
| Frequency of CYP2D6 Alleles in Patients | The frequency of 19 different CYP2D6 alleles in 287 patients is determined. In 2 out of all 289 patients the determination was not possible due to technical problems. Remark: each participant possesses a) two individual CYP2D6 alleles, b) from the combination of these two alleles one individual genotype is derived and c) from this genotype the genetically determined metabolizer status (PM, IM, NM, UM) is derived. | 1 Year | 
| Frequency of CYP2D6 Genotypes in Patients | The frequency of 61 different CYP2D6 genotypes in 287 patients is determined. In 2 out of all 289 patients the determination was not possible due to technical problems. Remark: each participant possesses a) two individual CYP2D6 alleles, b) from the combination of these two alleles one individual genotype is derived and c) from this genotype the genetically determined metabolizer status (PM, IM, NM, UM) is derived. | 1 Year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants in Whom the Family Physician Considered Prior Knowledge of Their Metabolizer Status Important Before the CYP2D6-specific Drug Was Prescriped. | In how many patients would family physician's knowledge of the CYP 2D6 metabolizer status (ultrarapid (UM), normal (NM), intermediate (IM) and poor (PM)) have been of importance before prescribing a CYP2D6 specific drug. Remark: The relevant drug has already already been prescribed before analysis has been taken place. | 1 Year | 
| Specific Number of Patients of the Whole Practice Population Whose Electronic Health Records (EHRs) Were Assessed. | The specific number of participants of the practice population with a prescription of drugs metabolized by CYP 2D6 within the last 3 years. These data were extracted from the electronic health records (EHRs) of the practice office. For this data extraction enrollement in the study and signing an informed consent was not necessary. No other data (i.e. baseline assessments, other outcome measures and adverse events) were collected in this group. | 1 Year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cytochrome P 450 CYP2D6 Variants, Genetic polymorphism, Practice, Family, Drug metabolism